Renaissance Technologies (RenTech)'s CGEM Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC (Rentech)) currently holds 631,706 shares of Cullinan Therapeutics, Inc. (CGEM) worth $6.54 M, representing 0.01% of the portfolio. First purchased in 2021-Q2, this medium-term investment has been held for 19 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in CGEM, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2022, adding 293,600 shares. Largest reduction occurred in Q3 2024, reducing 139,908 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Cullinan Therapeutics (CGEM) Holding Value Over Time
Track share changes against reported price movement
Quarterly Cullinan Therapeutics (CGEM) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +102,298 | Add 19.32% | 631,706 | $10.35 |
| Q3 2025 | +194,883 | Add 58.26% | 529,408 | $5.93 |
| Q2 2025 | -28,483 | Reduce 7.85% | 334,525 | $7.53 |
| Q1 2025 | +172,500 | Add 90.55% | 363,008 | $7.57 |
| Q4 2024 | -91,292 | Reduce 32.40% | 190,508 | $12.18 |
| Q3 2024 | -139,908 | Reduce 33.18% | 281,800 | $16.74 |
| Q2 2024 | +100,608 | Add 31.33% | 421,708 | $17.44 |
| Q1 2024 | +57,012 | Add 21.59% | 321,100 | $17.04 |
| Q4 2023 | +41,388 | Add 18.58% | 264,088 | $10.19 |
| Q3 2023 | -22,900 | Reduce 9.32% | 222,700 | $9.05 |
| Q2 2023 | +6,400 | Add 2.68% | 245,600 | $0.01 |
| Q1 2023 | -68,500 | Reduce 22.26% | 239,200 | $0.01 |
| Q4 2022 | +5,505 | Add 1.82% | 307,700 | $0.01 |
| Q3 2022 | +8,595 | Add 2.93% | 302,195 | $12.82 |
| Q2 2022 | +293,600 | New Buy | 293,600 | $12.82 |
| Q1 2022 | -26,600 | Sold Out | 0 | $0.00 |
| Q4 2021 | +26,600 | New Buy | 26,600 | $15.41 |
| Q3 2021 | -25,982 | Sold Out | 0 | $0.00 |
| Q2 2021 | +25,982 | New Buy | 25,982 | $25.75 |
Renaissance Technologies (RenTech)'s Cullinan Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Cullinan Therapeutics, Inc. (CGEM) in Q2 2021, acquiring 25,982 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Cullinan Therapeutics, Inc. (CGEM) for 19 quarters since Q2 2021.
Renaissance Technologies (RenTech)'s largest addition to Cullinan Therapeutics, Inc. (CGEM) was in Q2 2022, adding 293,600 shares worth $3.76 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC (Rentech), owns 631,706 shares of Cullinan Therapeutics, Inc. (CGEM), valued at approximately $6.54 M.
As of the Q4 2025 filing, Cullinan Therapeutics, Inc. (CGEM) represents approximately 0.01% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Cullinan Therapeutics, Inc. (CGEM) was 631,706 shares, as reported at the end of Q4 2025.